The new generation antimicrobial peptides

Our workContact us

 Latest news:

25th July 2023, A recently completed study in an in vivo ferret model shows very compelling results for LTX-109 compared to placebo in the treatment of Influenza virus infection.

About us

Pharma Holdings AS develops novel drugs for treatment of microbial infections.

Our cationic peptidomimetic is the result of world-class research in the field of lytic

The lead compound LTX-109 is engineered based on an antimicrobial sequence in a
naturally occurring peptide. Its mode of action with a low likelihood for development of
resistance, ensures a sustainable way of fighting infections.

Pharma Holdings is developing antiviral drugs for the huge unmet medical need
for effective treatment against respiratory virus diseases with pandemic potential,
and topical treatments for bacterial infections and doing so with low propensity
for development of resistance.


Wide, rapid action combined with unlikely resistance development

The compound LTX-109 has a proven effect against enveloped viruses, fungi and a variety of bacteria, both gram positives and gram negatives, including multi-resistant bacteria such as MRSA, and difficult-to-treat bacteria such as Pseudomonas aeruginosa in addition to biofilm. It exerts its virucidal, and bactericidal effect through disrupting the integrity of the bacterial cell membrane or the viral envelope, inducing lysis of the pathogen. The rapid mechanism of actionnot only enables treating infections faster, but also reduces the likelihood of resistance to our drug.

"We have shown that LTX-109 is very effective at eliminating bacterial biofilms formed by Pseudomonas aeruginosa, in this case killing it at only four times the concentration needed to kill planktonic, non-biofilm bacteria. This level of efficacy is quite unheard of with most other antibiotics."

– Prof. John Sigurd Svendsen


A privately owned Norwegian biopharmaceutical company

Pharma Holdings AS is a privately owned biopharmaceutical company with offices in Oslo and Tromsø, Norway. Our goal is to become one of the market leaders in the antimicrobial space. Originating from the well-known Scandinavian biotech “hub”, Pharma Holdings represent a compelling business case: Proprietary patented technology, acknowledged scientific experts, a highly competent management team, and a constantly growing market demand for our solutions.

Sustainable antimicrobial combat

Our vision is to contribute in the constant battle against global infections in a eco-friendly way by developing new potent drugs based on the nature’s on defense mechanism.